Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
What does a small/medium pharma-biotech need to do to get on BigPharma’s radar?<br />Mark McBride <br />Managing Director,...
Key Global Issue<br />BigPharma are losing exclusivity on their blockbuster products as they come off patent.<br />This le...
Key Global Issue – Example 1<br />World’s two biggest selling drugs both off-patent by end of 2012<br />Lipitor: $13b annu...
Key Global Issue – Example 2<br />2010: <br />AstraZeneca & GlaxoSmithKline announce:<br />combined 27,000 job cuts (nearl...
Opportunity<br />As BigPharma embraces Open Innovation it puts aside its traditional “only-invented-here” attitude. <br />...
Problem<br />How to get on to the radar when less than 15% of interactions with BigPharma are even reviewed?<br />Focus: t...
Structure of Workshop<br />Understand where your IP fits into the global marketplace<br />Understand what drives your part...
Global Market – Therapeutic Areas<br />Source: Pullan Consulting<br />
Global Market - Molecules<br />
Global Market – Deal Stages<br />Biotech Alliances with Big Pharma<br />Alliances from 2005 – 2010<br />2,114 deals announ...
Global Market – Deal Stages<br />Biotech Alliances with Big Pharma<br />
Deal Stages (2005-9 v 2010)<br />
Global Market & your IP<br />Where does your IP fit into the Global Marketplace?<br />Is your IP potential strong when com...
Is BigPharma correct for you?<br />If your IP does not match BigPharma’s needs, or your partner is looking to In-License o...
Understand your Partner<br />Shareholder needs (public/private) – are they risk averse?<br />What in your USPs will excite...
What Partnership is best for you?<br />Be open-minded – the market is fluid and so must you.<br />Licensing (losing popula...
Action Items - 1<br />Have a Coherent Plan from Day 1:<br />ManagementTeam<br />Understand your own IP & USPs<br />What so...
Action Items - 2<br />Raise your profile:<br />Build a story (benefits as well as science)<br />Engage a good PR Company<b...
Innovaro Pharmalicensing<br />Partnering Solutions for the LifeSciences<br />Innovaro Pharmalicensing is a leading resourc...
Upcoming SlideShare
Loading in …5
×

Workshop: Science City York April 2011

1,452 views

Published on

  • Be the first to comment

  • Be the first to like this

Workshop: Science City York April 2011

  1. 1. What does a small/medium pharma-biotech need to do to get on BigPharma’s radar?<br />Mark McBride <br />Managing Director, Innovaro Pharmalicensing <br />Science City York, April 2011<br />
  2. 2. Key Global Issue<br />BigPharma are losing exclusivity on their blockbuster products as they come off patent.<br />This leads to <br />fall in revenues, and <br />pressure from shareholders as shareholder value falls<br />
  3. 3. Key Global Issue – Example 1<br />World’s two biggest selling drugs both off-patent by end of 2012<br />Lipitor: $13b annual sales<br />Plavix: $6b annual sales<br />In total, more than $90b of annual “blockbuster” sales as of January 2008 will be off-patent by the end of 2012<br />Consequence: massive cuts are demanded, hitting R&D Groups.<br />
  4. 4. Key Global Issue – Example 2<br />2010: <br />AstraZeneca & GlaxoSmithKline announce:<br />combined 27,000 job cuts (nearly 20% of workforce), largely from R&D<br />plant closures<br />reduction in areas of therapeutic focus<br />future pipeline development driven by external acquisition/partnering of IP (opportunity)<br />
  5. 5. Opportunity<br />As BigPharma embraces Open Innovation it puts aside its traditional “only-invented-here” attitude. <br />Small/medium pharma-biotechs have opportunity to put themselves in front of BigPharma and highlight innovative IP.<br />
  6. 6. Problem<br />How to get on to the radar when less than 15% of interactions with BigPharma are even reviewed?<br />Focus: this workshop will discuss how to manage your visibility and ensure you have the best opportunity to partner successfully<br />
  7. 7. Structure of Workshop<br />Understand where your IP fits into the global marketplace<br />Understand what drives your partner<br />Understand what partnership is correct<br />What to do next<br />
  8. 8. Global Market – Therapeutic Areas<br />Source: Pullan Consulting<br />
  9. 9. Global Market - Molecules<br />
  10. 10. Global Market – Deal Stages<br />Biotech Alliances with Big Pharma<br />Alliances from 2005 – 2010<br />2,114 deals announced<br />Stage at Deal Signing<br />Discovery 901<br />Lead Molecule 77<br />Preclinical 256<br />Phase I 155<br />Phase II 179<br />Phase III 219<br />Approved 357<br />Source: Deloitte Recap LLC<br />
  11. 11. Global Market – Deal Stages<br />Biotech Alliances with Big Pharma<br />
  12. 12. Deal Stages (2005-9 v 2010)<br />
  13. 13. Global Market & your IP<br />Where does your IP fit into the Global Marketplace?<br />Is your IP potential strong when compared to BigPharma’s key areas of interest?<br />As BigPharma is risk averse then position your proposal to best match their needs, <br />otherwise….<br />
  14. 14. Is BigPharma correct for you?<br />If your IP does not match BigPharma’s needs, or your partner is looking to In-License only at PIIb+ then consider Specialty Pharma instead<br />Reactive<br />Committed<br />Consequence<br />Proportional<br />
  15. 15. Understand your Partner<br />Shareholder needs (public/private) – are they risk averse?<br />What in your USPs will excite them?<br />Look at their pipelines<br />Talk to their scouts as soon as possible<br />Bring them solutions, not just pure science <br />
  16. 16. What Partnership is best for you?<br />Be open-minded – the market is fluid and so must you.<br />Licensing (losing popularity) – be prepared to battle for significant up-fronts & milestones.<br />CRADAs (gaining popularity)<br />gets BigPharma in early (but not necessarily committed)<br />correct data generated <br />
  17. 17. Action Items - 1<br />Have a Coherent Plan from Day 1:<br />ManagementTeam<br />Understand your own IP & USPs<br />What sort of Partner will be best for you?<br />Understand prospective partner’s needs, and best deal structure<br />Data Package (budget for this from start)<br />Inject business reality & educate shareholder expectations<br />
  18. 18. Action Items - 2<br />Raise your profile:<br />Build a story (benefits as well as science)<br />Engage a good PR Company<br />Talk to the Scouts<br />Engage Opinion Leaders<br />Engage Innovaro Pharmalicensing <br />
  19. 19. Innovaro Pharmalicensing<br />Partnering Solutions for the LifeSciences<br />Innovaro Pharmalicensing is a leading resource for partnering, licensing and business development across the lifescience and biopharmaceutical industries<br />Through a unique offering combining Partnering Search and on-line Profiling services, the international biopharmaceutical, lifescience & healthcare industries utilise Innovaro Pharmalicensing to identify and engage with prospective licensing, marketing and discovery/ development partners around the world. <br />

×